Imagen de Portada

Editorial: Sounding the alarm—The rising global burden of adolescent and young adult alcohol‐related liver disease

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Victoria T. Kronsten, Debbie L. Shawcross
Formato:	Artículo Open Access
Publicado:	Wiley 2024
Materias:	Alimentary Pharmacology & Therapeutics
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Global epidemiology of alcohol‐associated liver disease in adolescents and young adults
por: Pojsakorn Danpanichkul, et al.
Publicado: (2024)

Editorial: Crystalising the burden of steatotic liver disease—Authors' reply
por: Carolin V. Schneider, et al.
Publicado: (2024)

Editorial: Paradox of liver fat content in the spectrum of non‐alcoholic fatty liver disease
por: Sung Won Chung, et al.
Publicado: (2024)

Letter: Reflections on the significance of myokines in alcohol‐associated liver disease
por: Yaomin Wang, et al.
Publicado: (2024)

Myokines are associated with progression, course and mortality in alcohol‐associated liver disease
por: Parminder Kaur, et al.
Publicado: (2024)

Socio‐economic association of alcohol use disorder and cardiovascular and alcohol‐associated liver disease from 2010 to 2019
por: Pojsakorn Danpanichkul, et al.
Publicado: (2024)

Prevalence of at‐risk MASH, MetALD and alcohol‐associated steatotic liver disease in the general population
por: Carolin V. Schneider, et al.
Publicado: (2024)

Cardiometabolic criteria as predictors and treatment targets of liver‐related events and cardiovascular events in metabolic dysfunction‐associated steatotic liver disease
por: Nobuharu Tamaki, et al.
Publicado: (2024)

Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality
por: Nobuharu Tamaki, et al.
Publicado: (2024)

Letter: Optimising public health policies to combat alcohol‐associated liver disease in youth—Addressing key methodological and regional challenges
por: Rui Zhang, et al.
Publicado: (2024)

Editorial: Updated epidemiology of steatotic liver disease in people with HIV in the United States
por: Richie Manikat, et al.
Publicado: (2024)

Editorial: The tsunami of steatotic liver disease in India, the Asia‐Pacific region and the world
por: Abdel‐Aziz Shaheen, et al.
Publicado: (2024)

Editorial: The tsunami of steatotic liver disease in India, the Asia‐Pacific region and the world—Authors' reply
por: Manya Prasad, et al.
Publicado: (2024)

Editorial: Updated epidemiology of steatotic liver disease in people withHIVin the United States—Authors' reply
por: Samer Gawrieh, et al.
Publicado: (2024)

Editorial: Using machine learning to predict significant fibrosis in metabolic dysfunction‐associated steatotic liver disease
por: Richie Manikat, et al.
Publicado: (2024)

Review article: Oesophageal disorders in chronic liver disease
por: Francisco Idalsoaga, et al.
Publicado: (2024)

UK guideline on the transition and management of childhood liver diseases in adulthood
por: Deepak Joshi, et al.
Publicado: (2024)

Letter: Zinc and selenium—Potential biomarkers for chronic liver disease?
por: Zhuo Li, et al.
Publicado: (2024)

Maladaptive weight control and eating behaviours in female adolescents/young adults are associated with increased risk of irritable bowel syndrome in adulthood: Results from the Growing Up Today Study (GUTS)
por: Keming Yang, et al.
Publicado: (2024)

Editorial: Muscles at the expense of liver injury. Is it worth it?
por: C. Stephens
Publicado: (2024)

Editorial: The future of managing drug induced liver injury
por: Amanda Nicoll
Publicado: (2024)

Letter: Prioritising osteosarcopenia assessment in the ongoing care of patients with cholestatic liver diseases
por: Ivan Arcari, et al.
Publicado: (2024)

Prevalence and prognostic value of zinc and selenium deficiency in advanced chronic liver disease
por: Nina Dominik, et al.
Publicado: (2024)

Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study
por: Yewan Park, et al.
Publicado: (2024)

Steatotic liver disease‐associated all‐cause/cause‐specific mortality in the United States
por: Donghee Kim, et al.
Publicado: (2024)

Letter: Potential impact of Helicobacter pylori infection on oesophageal disorders in chronic liver disease
por: Jannis Kountouras, et al.
Publicado: (2024)

Letter: Helicobacter pylori and metabolic syndrome‐related von Willebrand factor and plasminogen activator inhibitor‐1 activity levels for outcome prediction of advanced chronic liver disease
por: Jannis Kountouras, et al.
Publicado: (2024)

Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction‐associated steatotic liver disease
por: Nabil Noureddin, et al.
Publicado: (2024)

Meta‐analysis: Efficacy and safety of fibroblast growth factor 21 analogues for the treatment of non‐alcoholic steatohepatitis and non‐alcoholic steatohepatitis‐related fibrosis
por: Rutao Lin, et al.
Publicado: (2024)

Impacts of glucagon‐like peptide‐1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction‐associated steatotic liver disease cirrhosis and type 2 diabetes
por: Mohamed I. Elsaid, et al.
Publicado: (2024)

The overlap with metabolic dysfunction‐associated steatotic liver disease negatively affects outcomes of primary biliary cholangitis
por: María Hernández‐Pérez, et al.
Publicado: (2024)

Letter: Potential impact ofHelicobacter pyloriinfection on oesophageal disorders in chronic liver disease—Authors' reply
por: Francisco Idalsoaga, et al.
Publicado: (2024)

Glycaemic control is a modifiable risk factor for hepatocellular carcinoma and liver‐related mortality in patients with diabetes
por: Xianhua Mao, et al.
Publicado: (2024)

Editorial: Redefining liver health—Personalised approach to assessment of serum ALT in clinical practice
por: Basile Njei, et al.
Publicado: (2024)

Systematic review with meta‐analysis: Steatosis severity and subclinical atherosclerosis in metabolic dysfunction‐associated steatotic liver disease
por: Mohamad Jamalinia, et al.
Publicado: (2024)

Insulin‐like growth factor‐1 in cirrhosis is linked to hepatic dysfunction and fibrogenesis and predicts liver‐related mortality
por: Lukas Hartl, et al.
Publicado: (2024)

Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis ‐ prevalence, clinical impact, economic implications and management strategies
por: Pegah Golabi, et al.
Publicado: (2024)

Editorial: Solving the acute kidney injury puzzle in alcohol‐associated hepatitis—Challenges and insights
por: Vishnu Girish, et al.
Publicado: (2024)

Poor accuracy and sustainability of the first‐step FIB4 EASL pathway for stratifying steatotic liver disease risk in the general population
por: Antonio De Vincentis, et al.
Publicado: (2024)

Prevalence and risk factors of metabolic dysfunction‐associated steatotic liver disease in south Central Uganda: A cross‐sectional survey
por: Rocio Enriquez, et al.
Publicado: (2024)